Bris­tol My­ers Squibb walks on Op­di­vo's FDA nod for small-cell lung can­cer af­ter mid­dling OS da­ta could­n't back ap­proval

In a pitched bat­tle against Mer­ck’s Keytru­da, Bris­tol My­ers Squibb’s im­munother­a­py head­lin­er Op­di­vo land­ed a ma­jor sal­vo with a ground­break­ing FDA ap­proval for cer­tain lung …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER